Butorphanol Nasal Spray CIV
Generic Name and Formulations:
Butorphanol tartrate 1mg/spray; nasal spray.
Various generic manufacturers
Indications for Butorphanol Nasal Spray:
Pain management when opioid analgesia is appropriate.
≥18 years: initially 1 spray in 1 nostril, repeat after 60–90 minutes if needed (Elderly: 90–120 minutes); may repeat in 3–4 hours. Or, may give 1 spray in each nostril, may repeat after 3–4 hours.
<18 years: not recommended.
Head injury. Increased intracranial pressure. Biliary tract surgery. Respiratory, cardiac, renal, or hepatic dysfunction. MI. Ventricular dysfunction. Coronary insufficiency. Hypertension. May precipitate withdrawal in narcotic addicts. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Nasal vasoconstrictors delay onset. May be antagonized by concomitant (within 30 minutes) sumatriptan nasal spray.
Sedation, dizziness, nasal congestion, insomnia, GI upset, respiratory depression, sweating, hypo- or hypertension, rash, vasodilation, palpitation, tinnitus, respiratory and CNS effects.
Formerly known under the brand name Stadol NS.
Nasal Spray 2.5mL (8–15 sprays)—Contact supplier.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|